23511-50-4

Basic information

• Product Name: 2-CHLORO-N-CYCLOHEPTYLACETAMIDE
• Synonyms: 2-CHLORO-N-CYCLOHEPTYLACETAMIDE;AKOS BBS-00006518;CHEMBRDG-BB 5704895;2-chloro-N-cycloheptylacetamide(SALTDATA: FREE);2-chloro-N-cycloheptyl-ethanamide
• CAS NO: 23511-50-4
• Molecular Formula: C9H16ClNO
• Molecular Weight: 189.68
• Mol File: 23511-50-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 69.5-72.0 °C
• Boiling Point: 340.9°C at 760 mmHg
• Flash Point: 160°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 8.31E-05mmHg at 25°C
• Refractive Index: 1.483
• PKA: 13.97±0.20(Predicted)
• CAS DataBase Reference: 2-CHLORO-N-CYCLOHEPTYLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-CYCLOHEPTYLACETAMIDE(23511-50-4)
• EPA Substance Registry System: 2-CHLORO-N-CYCLOHEPTYLACETAMIDE(23511-50-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 23511-50-4(Hazardous Substances Data)

Usage

General Description

2-CHLORO-N-CYCLOHEPTYLACETAMIDE is a chemical compound with the molecular formula C9H16ClNO. It is an amide derivative with a chlorine atom and a cycloheptyl group attached to the nitrogen and carbon atoms, respectively. 2-CHLORO-N-CYCLOHEPTYLACETAMIDE is primarily used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical products. It is also utilized in research and development for the creation of new chemical compounds with potential therapeutic applications. The compound's structural characteristics make it a versatile component for the development of diverse pharmaceutical agents. Additionally, it is important to handle and store this chemical compound with proper safety precautions due to its potential toxicity and reactivity.

InChI:InChI=1/C9H16ClNO/c10-7-9(12)11-8-5-3-1-2-4-6-8/h8H,1-7H2,(H,11,12)

Upstream product

• 5452-35-7 cycloheptanamine 
• 79-04-9 chloroacetyl chloride 
• 502-41-0 cycloheptanol 
• 107-14-2 chloroacetonitrile 

Relevant articles and documents

Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts

Glucocorticoids form a critical component of chemotherapy regimens for pediatric acute lymphoblastic leukemia (ALL) and the initial response to glucocorticoid therapy is a major prognostic factor, where resistance is predictive of poor outcome. A high-throughput screen identified four thioimidazoline-containing compounds that reversed dexamethasone resistance in an ALL xenograft derived from a chemoresistant pediatric ALL. The lead compound (1) was synergistic when used in combination with the glucocorticoids, dexamethasone or prednisolone. Synergy was observed in a range of dexamethasone-resistant xenografts representative of B-cell precursor ALL (BCP-ALL) and T-cell ALL. We describe here the synthesis of twenty compounds and biological evaluation of thirty two molecules that explore the structure-activity relationships (SAR) of this novel class of glucocorticoid sensitizing compounds. SAR analysis has identified that the most effective dexamethasone sensitizers contain a thioimidazoline acetamide substructure with a large hydrophobic moiety on the acetamide. This journal is